S1 Ep215: Navigating The Dynamic Landscape of Stem Cell Transplantation
About this episode
The episode discusses advancements in stem cell transplantation, focusing on omidubicel and its impact on patient outcomes.
In a cobranded episode between Oncology on the Go , hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of graft-versus-host disease (GVHD) among transplantation recipients, and strategies for providing effective prophylaxis during treatment, among other topics. According to Horwitz, omidubicel has served as an “important graft source” for pediatric patients while improving cord blood transplantation for adults since its FDA approval in April 2023 for patients 12 years and older with hematologic malignancies. He also spoke to the importance of the FDA’s approval of the agent in December 2025 for patients with severe aplastic anemia and no compatible donors following reduced intensity conditioning. Regarding those with severe aplastic anemia, he noted that omidubicel may considerably improve the…
More episodes of Oncology On The Go
- S1 Ep217: Integrating Exercise and Lifestyle Intervention Into Oncologic Therapy
- S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview
- S1 Ep214: Are Zedoresertib and Lunresertib an Efficacious Combo Across Solid Tumors?
- S1 Ep213: What Does the Future Hold for Immune Effector Cell Therapies?
- S1 Ep211: Exploring and Managing Gastrointestinal-Related CAR T-Cell Lymphomas
- S1 Ep210: Elevating Precision Medicine Across Different Oncologic Populations
Explore listener stats, chart rankings, contacts and more on the Oncology On The Go podcast page.